Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Paratek Pharmaceuticals Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Paratek Pharmaceuticals Inc. market cap is $127.83M.
What is the 52-week high for Paratek Pharmaceuticals Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Paratek Pharmaceuticals Inc. 52 week high is $3.65 as of September 29, 2025.
What is the 52-week low for Paratek Pharmaceuticals Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Paratek Pharmaceuticals Inc. 52 week low is $1.29 as of September 29, 2025.
What is Paratek Pharmaceuticals Inc. stock price today?
Paratek Pharmaceuticals Inc. stock price today is $2.23.
What was Paratek Pharmaceuticals Inc. stock price yesterday?
Paratek Pharmaceuticals Inc. stock price yesterday was $2.19.
What is the PE ratio of Paratek Pharmaceuticals Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Paratek Pharmaceuticals Inc.’s P/E ratio is -2.00.
What is the Price-to-Book ratio of Paratek Pharmaceuticals Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Paratek Pharmaceuticals Inc. P/B ratio is -0.6344.
What is Paratek Pharmaceuticals Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Paratek Pharmaceuticals Inc.'s EBITDA is -7.78.
What is the 50-day moving average of Paratek Pharmaceuticals Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Paratek Pharmaceuticals Inc. 50-day moving average is $2.20.
